AtaiBeckley (ATAI) Proxy filing summary

Executive summary

• Entered into a definitive agreement to be acquired by Eli Lilly and Company, aiming to accelerate neuroscience programs and mental health treatment development.

• Transaction expected to close in Q3 2026, pending shareholder approval and customary conditions.

• Operations will continue independently until closing, with no changes to existing agreements or vendor relationships.

Voting matters and shareholder proposals

• Shareholders will vote on the adoption of the Merger Agreement at a special meeting.

• Proxy materials, including the definitive proxy statement and proxy card, will be distributed to eligible stockholders.

Board of directors and corporate governance

• Directors, executive officers, and certain employees may be considered participants in the proxy solicitation.

• Information on director and executive officer stock ownership is available in the 2026 Proxy Statement and recent SEC filings.